Sanofi buoyed by positive financial results

7 February 2019

French pharma major Sanofi (Euronext: SAN) has been boosted by a positive end of year financial results statement, showing the firm took in 8.9 billion euros ($10.1 billion) in the final three months of 2018, an increase of 3.5%, with sales growth driven by its specialty care and vaccine units.

Net income for the fourth quarter was 254 million euros, or 20 euro cents per share. For the whole year, Sanofi took in 34.4 billion euros, with net income of 4.3 billion euros, or 3.45 euros per share.

Sales at US-based biotech subsidiary Sanofi Genzyme were up 37.4% in the fourth quarter, driven by the immunology and rare blood disorder franchises. Vaccines sales increased 9.7%, driven by an influenza differentiation strategy and by Menactra.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK